Table 1.

Schematic of Study Design.

Cohort	Group	Study Product	Number
1*	A	10 μg Sm-TSP-2/Alhydrogel®	10
	B	10 μg Sm-TSP-2/Alhydrogel®/GLA-AF	10
	C	Placebo†	4
2*	D	30 μg Sm-TSP-2/Alhydrogel®	10
	E	30 μg Sm-TSP-2/Alhydrogel®/GLA-AF	10
	F	Placebo†	4
3	G	100 μg Sm-TSP-2/Alhydrogel®	10
	H	100 μg Sm-TSP-2/Alhydrogel®/GLA-AF	10
	I	Placebo†	4
Total			72

^†Saline for injection.

^*Dose escalation decisions were made after the last subject in the cohort completed the 7 day post dose 1 visit.